Teva Pharmaceutical Industries Ltd.

Most revenue comes from selling manufactured goods outright, recognized when the product ships and the customer takes control of it, rather than from subscriptions or recurring service fees. Generic medicines make up the larger part of that revenue, alongside a branded specialty portfolio, licensing income tied to intellectual property and research collaborations, and a smaller distribution business.

Its scale is built physically, across many manufacturing plants in many countries producing very large volumes of standardized medicines, rather than from one dominant site, and it sits among several hundred other companies grouped as running a similar kind of production-and-approval system. Separately, a reading of its financial statements suggests that some of the returns generated relative to its size are shaped by borrowed capital rather than by operating growth alone.

It depends on raw materials bought on the open market, including some key inputs it identifies as coming from a single source, and on a mix of its own plants, including production of active ingredients it intends to divest, and outside contract manufacturers to turn those inputs into finished medicines. It also depends on keeping patents and regulatory approvals in force, on collaboration partners, and on one product class, generic medicines, for the largest part of its revenue.

McKesson Corporation and AmerisourceBergen Corporation, named as its major customers, account for a concentrated share of revenue, sitting between it and the retail pharmacy chains, mail-order distributors, independent pharmacies, hospitals, physician offices and managed-care organizations that ultimately carry or reimburse its medicines.

It operates the same general kind of production-and-approval system as several hundred other companies grouped this way, so that shape alone does not set it apart. Its own disclosures describe specific, measured positions within named categories, a share of national generic prescriptions and a share within one specialty injectable drug class, rather than an advantage described as one rivals cannot reproduce.

Its own filings tie continued revenue to keeping products under patent or regulatory protection and to securing new approvals, and describe its scale in terms of the output of a defined set of manufacturing plants rather than naming one single ceiling on growth. CompanyGraph groups this pattern, revenue depending on clearing a regulatory step before it can be earned, as common to this shape of company, though that is a general grouping rather than a specific measurement of where this company's own limit sits.

McKesson Corporation and AmerisourceBergen Corporation, its two named major customers, together account for a large, concentrated share of sales, and its filings separately flag dependence on single-source suppliers for some key raw materials and on maintaining patents, regulatory approvals and collaboration agreements, so losing any one of these carries outsized weight compared with a more diversified structure. Its net income has been negative in some recent years, and a separate assessment of its financial statements, drawing on several solvency-related measures at once, a composite distress indicator, the share of assets funded by debt, and debt measured against the cash its operations generate, places it under financial pressure from more than one direction at the same time.

Several regulatory and legal processes act on it at once: an appeal of a European competition-law fine, an appeal over how a government drug-price negotiation program is implemented, an investigation into how it lists patents for one product, and ongoing litigation tied to opioid medicines. It also operates under import, export, sanctions and tariff rules enforced by multiple national and multilateral authorities, and a large share of its revenue is earned in currencies other than the one it reports in.